LB Pharmaceuticals Inc cash flow statement LBRX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, LB Pharmaceuticals Inc used $35.2 million of cash from operations. It spent $52,000 on capital expenditures. Free cash flow was negative, at -$35.3 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
—
0
Stock-based compensation
13
4
Operating cash flow
-143
-35
Investing
Capital expenditures
1
0
Investing cash flow
-145
-40
Financing
Financing cash flow
234
303
Change in cash
Net change in cash
-54
227
Free cash flow
-144
-35
Per share
Free cash flow per share
-4.93
-4.38
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LBRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1691082
Former names
LB PHARMACEUTICALS INC. (until Dec 12, 2018)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.